The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Viveka
thanks again for sharing more info in depth
I hope you are right, Borsaci06. It benefits no one for the dispute to drag on. It could be that Secura Bio are just firing a shot across the bow – telling Midatech to make progress with the MTX110 trials or risk losing the panobinostat. There is a pressing need to find an effective therapy for DIPG. The median survival time is 9 months from diagnosis. There is no time to waste. MTX110 could be part of a new treatment paradigm – but the clinical data is needed, and NICE will be waiting for that:
https://www.nice.org.uk/guidance/indevelopment/gid-ta10573
The biggest difficulties are recruiting enough patients in a reasonable time frame (it’s a rare childhood cancer – 1000 per year globally) and having parents that can afford to pay to participate in the trial – most have to resort to charity events/organisations and ‘go fund me’. I do believe Midatech were providing the MTX110 to the UCSF trial at no cost – but the insertion of the CED catheters is a major operation and therefore it won’t be cheap.
I actually thought I'd found him on the i3e board (not a ramp believe me - it just relisted) - dude called magnus just created a profile a week a go and was posting multiple times a day and with the words, tone of voice and miss-spellings ... just like the 'major'.
question is are we talking minor_buyer or major_buyer ?
If the herd heard it was major_buyer.. well that could be fun !
And if the herd heard it was The major_buyer.. well that could be a lot of fun !!
small cap pick
All one word
************
Also being pumped on twitter regarding this trial
https://twitter.com/************
Viveka
I think
mtph is sure of Secura Bio`s unilateral termination of licence will be revoked
otherwise they would not state clinical development program of MTX110, our product for DIPG because
they need a supply/stock of Panobinostat for the trial
&
arrival of approximately $7.9 million in the accounts would be nice ( if/when )
USE OF PROCEEDS page 10
" to fund the clinical development program of MTX110, our product for DIPG and potentially other pediatric brain cancers.... "
http://otp.investis.com/clients/us/midatech/SEC/sec-show.aspx?Type=html&FilingId=14331812&CIK=0001643918&Index=10000
imo
Thanks for sharing the useful insight as usual Viveka. The MTX110 data is definitely overdue, they did add some extra cohorts at higher doses that were initially planned, which I see as good news. There has also been COVID - 19, which seems to be delaying many oncology studies and related procedures. Nonetheless it would help if we had an update.
Thank You Viveka
It’s a mixture. The positives are that panobinostat is one of the most effective drugs against DIPG tumour cells and through CED of MTX110 it can be given at very high concentrations. Its safety profile has been described as excellent so far and we are due data on the dose escalation component of the UCSF trial. In addition to the two DIPG trials for MTX110, a third efficacy trial in Zurich and Utrecht is about to start.
A fourth trial for a different form of brain tumour called medulloblastoma started in March:
https://clinicaltrials.gov/ct2/show/NCT04315064
There is a lot of interest in MTX110 as a possible new treatment for these difficult to treat brain tumours. That’s all positive.
The negatives are that the licensor doesn’t want the licensee to have access to the panobinostat. That dispute needs a prompt and, hopefully, amicable resolution. Plus, the trial at UCSF appears to be taking too long. A poster on here suggested that may have been one of the reasons why Secura wanted to terminate the license agreement.
Is this a positive thing or negative ?
Viveka
thank you for putting some light
Panobinostat was originally developed by Novartis. It got FDA approval in 2015 to treat Multiple Myeloma and was marketed under the name Farydak.
In June 2017, Midatech signed a global license agreement with Novartis to investigate panobinostat for treatment of brain cancers. They use their MidaSolve tech to dissolve the panobinostat and deliver it directly into the brain tumour using catheters – a technique called convection enhanced delivery (CED). The solubilised form of panobinostat is called MTX110.
Secura Bio acquired the global rights to Farydak from Novartis in March 2019. It now appears Secura want to extend the use of panobinostat to brain tumours, and as part of that development they are attempting to prevent Midatech using panobinostat in MTX110 by terminating the license. I can’t work out what Secura are playing at – they should be helping Midatech to develop MTX110. In return, Secura would receive royalty payments.
There are four active clinical trials using panobinostat to treat brain tumours. Two using it in tablet form (systemically) and two using it in soluble form (MTX110):
https://www.clinicaltrials.gov/ct2/results?cond=DIPG&term=Panobinostat&cntry=&state=&city=&dist=
In tablet form, the panobinostat is dispersed systemically – so it will be a lot more toxic to the body than MTX110. It will have to be given in large enough doses if it is to stand any chance of crossing the blood-brain barrier into the brain at therapeutic concentrations.
In contrast, MTX110 can be infused directly into the tumour at very high concentrations without producing systemic toxicity because the blood-brain barrier prevents the drug passing out of the brain.
The direct route into the tumour offered by MTX110 appears to me to be the superior option.
and also these
https://twitter.com/MarketCurrents/status/872411858476466177
https://twitter.com/Pharma_Leaders/status/875113226052173825
https://twitter.com/pharma_sector/status/874713287967068160
https://twitter.com/Market_Screener/status/874211702832812032
https://twitter.com/PharmaProcesses/status/873683734951800832
just found this on twitter.
@tenbagger8
#MTPH - Midatech Pharma
It seems that Secura Bio are currently performing a phase I study of Marizomib + Panobinostat for Children With DIPG:
https://clinicaltrials.gov/ct2/show/NCT04341311
They acquired the global rights for Farydak (Panobinostat) from Novartis.
https://twitter.com/tenbagger8/status/1272204490582753280
and that`s why trying to cancel the licence.
mtph must be aware of this trail
&
should have taken necessary steps
Secura took over Novartis. Now I see why they want Midatech out of the picture. It looks like they're working on a competing product.
The following tells me that MTPH got global licence for Panobinostat.
If so, how/where Secura Bio got this FARYDAK® (panobinostat) capsules 10/15/20mg
https://us.farydak.com/
06/07/2017 | 10:05am BST
7 June 2017
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, today announces that it has signed a global licensing agreement with Novartis for the oncology compound panobinostat.
https://www.marketscreener.com/MIDATECH-PHARMA-PLC-19157045/news/Midatech-Pharma-signs-global-agreement-for-panobinostat-24554089/
this is from trail
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Celgene
Secura Bio
Information provided by (Responsible Party):
Katherine Warren, MD, Dana-Farber Cancer Institute
Thought Panobinostat was Novartis?
here you go if you are lazy
https://clinicaltrials.gov/ct2/show/NCT04341311
if this is our Panobinostat
how come Secura Bio recruiting for this trial
Last Update Posted : August 11, 2020
they said licence terminated
https://dipg.org/dipg-treatment/active-clinical-trials/